TY - JOUR
T1 - Analgesic Effects of Botulinum Toxin in Children with CP
AU - Sandahl Michelsen, Josephine
AU - Normann, Gitte
AU - Wong, Christian
PY - 2018/4/19
Y1 - 2018/4/19
N2 - Experiencing pain is the greatest contributor to a reduced quality of life in children with cerebral palsy (CP). The presence of pain is quite common (~60%) and increases with age. This leads to missed school days, less participation, and reduced ambulation. Despite these alarming consequences, strategies to relieve the pain are absent and poorly studied. Moreover, it is difficult to evaluate pain in this group of children, especially in cases of children with cognitive deficits, and tools for pain evaluation are often inadequate. Botulinum toxin has been shown to alleviate pain in a variety of disorders and could potentially have an analgesic effect in children with CP as well. Even though most of the studies presented here show promising results, many also have limitations in their methodology as it is unlikely to capture all dimensions of pain in this heterogeneous group using only one assessment tool. In this review, we present a new way of examining the analgesic effect of botulinum toxin in children with CP using a variety of pain scores.
AB - Experiencing pain is the greatest contributor to a reduced quality of life in children with cerebral palsy (CP). The presence of pain is quite common (~60%) and increases with age. This leads to missed school days, less participation, and reduced ambulation. Despite these alarming consequences, strategies to relieve the pain are absent and poorly studied. Moreover, it is difficult to evaluate pain in this group of children, especially in cases of children with cognitive deficits, and tools for pain evaluation are often inadequate. Botulinum toxin has been shown to alleviate pain in a variety of disorders and could potentially have an analgesic effect in children with CP as well. Even though most of the studies presented here show promising results, many also have limitations in their methodology as it is unlikely to capture all dimensions of pain in this heterogeneous group using only one assessment tool. In this review, we present a new way of examining the analgesic effect of botulinum toxin in children with CP using a variety of pain scores.
KW - Analgesics/therapeutic use
KW - Botulinum Toxins/therapeutic use
KW - Cerebral Palsy/drug therapy
KW - Child
KW - Humans
KW - Muscle Spasticity/drug therapy
KW - Neuromuscular Agents/therapeutic use
KW - Pain/drug therapy
U2 - 10.3390/toxins10040162
DO - 10.3390/toxins10040162
M3 - Review
C2 - 29671771
SN - 2072-6651
VL - 10
JO - Toxins
JF - Toxins
IS - 4
M1 - 162
ER -